332 related articles for article (PubMed ID: 34756593)
1. Risk of Intracranial Hemorrhage Caused by Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation (from a Network Meta-Analysis of Randomized Controlled Trials).
Lv M; Wu T; Jiang S; Chen W; Zhang J
Am J Cardiol; 2022 Jan; 162():92-99. PubMed ID: 34756593
[TBL] [Abstract][Full Text] [Related]
2. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants.
Wolfe Z; Khan SU; Nasir F; Raghu Subramanian C; Lash B
J Thromb Haemost; 2018 Jul; 16(7):1296-1306. PubMed ID: 29723935
[TBL] [Abstract][Full Text] [Related]
4. Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis.
Ma F; Xu W; Chen J; Zhang J
Eur J Clin Pharmacol; 2023 Aug; 79(8):1013-1022. PubMed ID: 37310479
[TBL] [Abstract][Full Text] [Related]
5. Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.
Wu T; Lv C; Wu L; Chen W; Lv M; Jiang S; Zhang J
J Neurol; 2022 Feb; 269(2):664-675. PubMed ID: 33594452
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.
Archontakis-Barakakis P; Li W; Kalaitzoglou D; Tzelves L; Manolopoulos A; Giannopoulos S; Giamouzis G; Giannakoulas G; Batsidis A; Palaiodimos L; Ntaios G; Lip GYH; Kokkinidis DG
Br J Clin Pharmacol; 2022 Nov; 88(11):4663-4675. PubMed ID: 35853612
[TBL] [Abstract][Full Text] [Related]
7. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials.
Lin DS; Lo HY; Huang KC; Lin TT; Lee JK
J Am Heart Assoc; 2023 Dec; 12(23):e030380. PubMed ID: 38014696
[TBL] [Abstract][Full Text] [Related]
9. An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Suppah M; Kamal A; Saadoun R; Baradeiya AMA; Abraham B; Alsidawi S; Sorajja D; Fortuin FD; Arsanjani R
Am J Cardiol; 2023 Nov; 206():132-150. PubMed ID: 37703679
[TBL] [Abstract][Full Text] [Related]
10. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
[No Abstract] [Full Text] [Related]
11. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
13. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation.
Raposeiras-Roubín S; Alonso Rodríguez D; Camacho Freire SJ; Abu-Assi E; Cobas-Paz R; Rodríguez Pascual C; García Comesaña J; González-Carrero López A; Cubelos Fernández N; López-Masjuán Ríos Á; Cespón-Fernández M; Muñoz-Pousa I; Caneiro-Queija B; Rodríguez Albarrán A; Castañera SÁ; Guillén JV; Carpintero Vara A; Barreiro Pardal C; Domínguez-Erquicia P; Domínguez-Rodríguez LM; Díaz Fernández JF; Fernández Vázquez F; Iñíguez-Romo A
J Am Med Dir Assoc; 2020 Mar; 21(3):367-373.e1. PubMed ID: 31753740
[TBL] [Abstract][Full Text] [Related]
14. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
[No Abstract] [Full Text] [Related]
15. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.
Becattini C; Franco L; Beyer-Westendorf J; Masotti L; Nitti C; Vanni S; Manina G; Cattinelli S; Cappelli R; Sbrojavacca R; Pomero F; Marten S; Agnelli G
Int J Cardiol; 2017 Jan; 227():261-266. PubMed ID: 27843050
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis.
Mariani MV; Magnocavallo M; Straito M; Piro A; Severino P; Iannucci G; Chimenti C; Mancone M; Rocca DGD; Forleo GB; Fedele F; Lavalle C
J Thromb Thrombolysis; 2021 Feb; 51(2):419-429. PubMed ID: 33044735
[TBL] [Abstract][Full Text] [Related]
17. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trials.
de Lucena LA; Freitas MAA; Souza AKC; Silva CHA; Watanabe JMF; Guedes FL; Almeida JB; de Oliveira RA
J Thromb Thrombolysis; 2024 Mar; 57(3):381-389. PubMed ID: 38281231
[TBL] [Abstract][Full Text] [Related]
18. Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
Liu X; Xu ZX; Yu P; Yuan P; Zhu WG
Cardiovasc Drugs Ther; 2020 Aug; 34(4):569-578. PubMed ID: 32297024
[TBL] [Abstract][Full Text] [Related]
19. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Zirlik A; Bode C
J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543
[TBL] [Abstract][Full Text] [Related]
20. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
